Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

  • Nat Cancer. 2026 Jan;7(1):182-193. doi: 10.1038/s43018-025-01085-z.
Guangwen Yuan  #  1 ,  Ge Lou  #  2 ,  Jundong Li  #  3 ,  Mei Xu  4 ,  Xiaowei Liu  5 ,  Danbo Wang  6 ,  Keqiang Zhang  7 ,  Tao Zhu  8 ,  Xiumin Li  9 ,  Yi Huang  10 ,  Wei Duan  11 ,  Ke Wang  12 ,  Qi Zhou  13 ,  Guiling Li  14 ,  Chen Yang  15  16 ,  Jiajing Zhang  15  16 ,  Haolin Sun  16  17 ,  Renhong Tang  16  18 ,  Qingshui Li  19 ,  Lingying Wu  20  21
Affiliations
  • 1. Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • 2. Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.
  • 3. Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • 4. Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, China.
  • 5. Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, China.
  • 6. Department of Gynecology, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • 7. Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China.
  • 8. Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • 9. Department of Gynecologic Oncology, Linyi Cancer Hospital, Linyi, China.
  • 10. Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China.
  • 11. Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
  • 12. Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • 13. Department of Gynecologic Oncology, Chongqing Cancer Hospital, Chongqing, China.
  • 14. Department of Gynecologic Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • 15. Clinical Sciences, Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China.
  • 16. State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
  • 17. Clinical Statistics, Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China.
  • 18. Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China.
  • 19. Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. [email protected].
  • 20. Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [email protected].
  • 21. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Liaoning Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenyang, China. [email protected].
  • # Contributed equally.
PMID: 41514054 DOI: 10.1038/s43018-025-01085-z
Abstract

In the SCORES study ( NCT04908787 ), women with ovarian Cancer that progressed within 6 months after completing platinum-based therapy were randomized (2:1) to receive suvemcitug (1.5 mg kg-1), an antibody to vascular endothelial growth factor or placebo every 2 weeks, with chemotherapy (paclitaxel, topotecan or PEGylated liposomal doxorubicin). The primary endpoint was progression-free survival (PFS). The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, disease control rate, duration of response, quality of life, safety, pharmacokinetics and antidrug antibodies. Between June 5, 2021 and October 11, 2024, 421 participants were randomized (49.4% and 49.4% previously exposed to antiangiogenic agents and poly(ADP-ribose) polymerase inhibitors, respectively). Median PFS was 5.5 and 2.7 months in the suvemcitug and placebo arms, respectively (hazard ratio: 0.46, 95% confidence interval (CI): 0.35-0.60, P < 0.001), meeting the primary endpoint. Median OS was 15.3 versus 14.0 months, respectively (hazard ratio: 0.77, 95% CI: 0.60-0.99, P = 0.03). Decreased neutrophil count and decreased white blood cell count were the most common grade ≥3 treatment-emergent adverse events (TEAEs) in the suvemcitug arm. No suvemcitug-related grade 5 TEAE occurred. In conclusion, the addition of suvemcitug to chemotherapy significantly improved PFS and OS, with tolerable toxicities.

Products